April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Six Years Experience With the IOL-Vip® Implant in Patients With Macular Degeneration
Author Affiliations & Notes
  • C. O. Pierrottet
    Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital. Retinitis Association, Milan, Italy
  • G. Savaresi
    Retinitis Association, Milan, Italy
  • P. Ferri
    Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, Milan, Italy
  • S. Romano
    Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, Milan, Italy
  • N. Orzalesi
    Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, Milan, Italy
  • Footnotes
    Commercial Relationships  C.O. Pierrottet, None; G. Savaresi, None; P. Ferri, None; S. Romano, None; N. Orzalesi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3208. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. O. Pierrottet, G. Savaresi, P. Ferri, S. Romano, N. Orzalesi; Six Years Experience With the IOL-Vip® Implant in Patients With Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3208.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the long term effect of the IOL-Vip® (IOLs for Visually Impaired People) System intraocular implant and the visual outcome in different forms of macular degeneration.

Methods: : A retrospective study of 75 eyes of 50 patients (age range 36-85 years) with central scotoma due to different forms of macular degeneration (group I: 41 atrophic ARMD, group II: 17 myopic macular degeneration, group III: 3 macular hole, group IV: 14 Stargardt maculopathy) who underwent phacoemulsification with the implant of the IOL-Vip® system, an intraocular Galilean telescope composed of two IOLs with a magnifying effect of 1.3x (N. Orzalesi, C. Pierrottet, et al.. The IOL-Vip System. A Double Intraocular Lens Implant for Visual Rehabilitation of Patients with Macular Disease. Ophthalmology 114: 860-865, 2007). All patients underwent a preoperative simulation of the magnifying effect and a customized rehabilitation training program. Mean follow-up was 4,2 years (range 6 years - 3 months) and outcome measure was represented by logMAR visual acuity.

Results: : All the patient but one reported a visual acuity improvement from mean preop 1,3 logMAR to mean postop 0,68 logMAR. Preop simulation fitted with postop result in 78%, overestimated in 1% and underestimated in 21%. Secondary cataract developed in 18% of eyes which was treated with Yag laser capsulotomy. Seven months after surgery one eye in group I developed a wet form of ARMD treated with anti-VEGF. There were no complications related to surgery and the majority of patients were very satisfied of the procedure, though the best results were obtained in group III and IV.

Conclusions: : The IOL-Vip® system seems to be a safe and reliable procedure even in a long follow-up period. The result is strictly related to the dimension and shape of the retinal lesion allowing a better quality of the preferential retinal locus. Progression of atrophic macular lesions influences the visual outcome in the long period, but the magnifying effect maintains a visual efficacy.

Keywords: age-related macular degeneration • low vision • intraocular lens 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×